Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of food on alicaforsen modified release tablets
NCT03473626Phase 1Completed
- Sponsor
- Atlantic Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Apr 2018
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alicaforsen in inflammatory bowel disease (IBD) (2 arms), sponsored by Atlantic Pharmaceuticals. Primary endpoint: Pharmacokinetics at 24 hours. Started Mar 2018; status: completed.
02
Drugs
alicaforsen
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03473626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473626.